Kazama JJ - Search Results

1

Anticipated increase in the number of patients who require dialysis treatment among the aging population of Japan.

Wakasugi M, Kazama JJ, Narita I. Wakasugi M, et al. Among authors: kazama jj. Ther Apher Dial. 2015 Jun;19(3):201-6. doi: 10.1111/1744-9987.12266. Epub 2014 Dec 29. Ther Apher Dial. 2015. PMID: 25545737

2

Hypersensitivity to paraoxybenzoic Acid esters (parabens) in a dialysis patient.

Sato K, Kazama JJ, Wada Y, Maruyama H, Narita I, Gejyo F, Sugiyama K, Satoh H. Sato K, et al. Among authors: kazama jj. Nephron. 2002;92(3):728-9. doi: 10.1159/000064076. Nephron. 2002. PMID: 12372968

3

Association of the MCP-1 gene polymorphism A-2518G with carpal-tunnel syndrome in hemodialysis patients.

Omori K, Kazama JJ, Song J, Goto S, Takada T, Saito N, Sakatsume M, Narita I, Gejyo F. Omori K, et al. Among authors: kazama jj. Amyloid. 2002 Sep;9(3):175-82. doi: 10.3109/13506120209114819. Amyloid. 2002. PMID: 12408680

4

Successful perioperative blood purification therapy in patients with maintenance hemodialysis therapy who underwent living donor liver transplantation.

Kazama JJ, Takahashi N, Ito Y, Watanabe Y, Iino N, Iguchi S, Oyanagi A, Obayashi H, Ito S, Maruyama H, Narita I, Yamamoto S, Sato Y, Tsuchiya A, Ichida T, Gejyo F. Kazama JJ, et al. Clin Nephrol. 2003 Mar;59(3):229-33. doi: 10.5414/cnp59229. Clin Nephrol. 2003. PMID: 12653270

5

Circulating 1-84 PTH and large C-terminal PTH fragment levels in uremia.

Kazama JJ, Omori T, Ei I, Ei K, Oda M, Maruyama H, Narita I, Gejyo F, Shigematsu T, Fukagawa M. Kazama JJ, et al. Clin Exp Nephrol. 2003 Jun;7(2):144-9. doi: 10.1007/s10157-003-0226-2. Clin Exp Nephrol. 2003. PMID: 14586733

6

Development of hungry bone syndrome after rapid lowering of PTH with intravenous maxacalcitol therapy in a patient with non-uremic secondary hyperparathyroidism.

Kazama JJ, Suzuki K, Yokoseki A, Oyanagi A, Goto S, Shimada H, Maruyama H, Narita I, Gejyo F. Kazama JJ, et al. Clin Nephrol. 2003 Nov;60(5):369-71. doi: 10.5414/cnp60369. Clin Nephrol. 2003. PMID: 14640244

7

Pretreatment plasma intact parathyroid hormone and serum calcium levels, but not serum phosphate levels, predict the response to maxacalcitol therapy in dialysis patients with secondary hyperparathyroidism.

Oyama Y, Kazama JJ, Omori K, Higuchi N, Kameda S, Yamamoto S, Ito Y, Maruyama H, Narita I, Gejyo F. Oyama Y, et al. Among authors: kazama jj. Clin Exp Nephrol. 2005 Jun;9(2):142-7. doi: 10.1007/s10157-005-0342-2. Clin Exp Nephrol. 2005. PMID: 15980949 Clinical Trial.

8

Maxacalcitol therapy decreases circulating osteoprotegerin levels in dialysis patients with secondary hyperparathyroidism.

Kazama JJ, Omori K, Takahashi N, Ito Y, Maruyama H, Narita I, Gejyo F, Iwasaki Y, Fukagawa M. Kazama JJ, et al. Clin Nephrol. 2005 Jul;64(1):64-8. doi: 10.5414/cnp64064. Clin Nephrol. 2005. PMID: 16047647

9

Abeta-2M-amyloidosis and related bone diseases.

Kazama JJ, Yamamoto S, Takahashi N, Ito Y, Maruyama H, Narita I, Gejyo F. Kazama JJ, et al. J Bone Miner Metab. 2006;24(2):182-4. doi: 10.1007/s00774-005-0669-5. J Bone Miner Metab. 2006. PMID: 16502130 Review.

10

Etiology and prognostic significance of severe uremic pruritus in chronic hemodialysis patients.

Narita I, Alchi B, Omori K, Sato F, Ajiro J, Saga D, Kondo D, Skatsume M, Maruyama S, Kazama JJ, Akazawa K, Gejyo F. Narita I, et al. Among authors: kazama jj. Kidney Int. 2006 May;69(9):1626-32. doi: 10.1038/sj.ki.5000251. Kidney Int. 2006. PMID: 16672924 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

239 results

Search Page